News | August 22, 2010

Research Begins on Colorectal Cancer PET Agent

August 23, 2010 - A new, rapid method of labeling peptides with a fluorine-18 (F-18) positron-emission tomography (PET) radiotracer is being evaluated.

Immunomedics Inc. and GE Healthcare announced they have entered into a license and collaboration agreement for the evaluation of labeling technologies based on Immunomedics' patented F-18 peptide labeling method.

Immunomedics developed a rapid, stable, and efficient way of labeling peptides with F-18 by first conjugating the radioisotope with aluminum. This is the first method of binding F-18 to peptides via an aluminum conjugate. F-18 labeled peptides have been shown to be stable enough to produce quality PET images of receptor-expressing tumors in animals and in pretargeting studies using a human colorectal cancer model.

Terms of the agreement were not disclosed, but GE Healthcare will fund all costs related to the collaboration.

For more information: www.immunomedics.com

Related Content

Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

News | Nuclear Imaging | December 26, 2019
December 26, 2019 — The Feinstein Institutes for Medical R...
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
 Phoenix’s fusion neutron generation technology.
News | Radiopharmaceuticals and Tracers | October 28, 2019
October 28, 2019 — Phoenix LLC and Shine Medical Technologies LLC, nuclear technology companies focused on near-term
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
A SPECT nuclear scan of the heart to show perfusion defects in the myocardium due to coronary artery blockages or heart attack. The imaging uses the Mo-99 based medical imaging isotope Tc-99m. The U.S. government has created policy to move away from use of highly enriched uranium (HEU) to low-enriched uranium (LEU) for Mo-99 isotope production, but there is one hold out who has not yet converted before a 2020 deadline. Photo courtesy of Philips Healthcare.

A SPECT nuclear scan of the heart to show perfusion defects in the myocardium due to coronary artery blockages or heart attack. The imaging uses the Mo-99 based medical imaging isotope Tc-99m. The U.S. government has created policy to move away from use of highly enriched uranium (HEU) to low-enriched uranium (LEU) for Mo-99 isotope production, but there is one holdout who has not yet converted before a 2020 deadline. Photo courtesy of Philips Healthcare.

Feature | Nuclear Imaging | August 30, 2019 | Dave Fornell, Editor
In a surprising move, the National Institute for Radioelements (IRE) has applied for a new license to export highly e
University of Alabama at Birmingham Leading Production of Theranostic Radioisotope

Image courtesy of the University of Alabama at Birmingham

News | Radiopharmaceuticals and Tracers | August 29, 2019
The University of Alabama at Birmingham, in conjunction with researchers at the University of Wisconsin and Argonne...
United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT
News | PET-CT | August 15, 2019
United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system...
ASRT Supports Radiopharmaceutical Reimbursement Bill
News | Radiopharmaceuticals and Tracers | August 02, 2019
The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure...
NorthStar Medical Radioisotopes Awarded $30 Million by U.S. Department of Energy
News | Radiopharmaceuticals and Tracers | July 26, 2019
NorthStar Medical Radioisotopes LLC has been awarded $15 million in a cooperative agreement with the U.S. Department of...